Browsing Tag
HER2-targeted immunotherapy
1 post
OS Therapies’ OST-HER2 achieves milestone in osteosarcoma treatment
OS Therapies, Inc., a clinical-stage biotechnology company, has announced data from its Phase 2b trial of OST-HER2, an…